Table 2. Replication results from the TwinsUK study for rs4329.

metabolic trait	n (non-users)	beta (non-users)	p-value (non-users)	n (users)	beta (users)	p-value (users)	n AA	beta AA	p-value AA	n AG	beta AG	p-value AG	n GG	beta GG	p-value GG
aspartylphenylalanine	574	-0.436	3.80x10-10	56	-0.017	0.939	174	-0.764	0.0001	279	-0.464	0.005	121	-0.059	0.731
aspartylphenylalanine / HWESASXX	574	-0.233	2.15x10-06	56	-0.158	0.308	174	-0.441	0.001	279	-0.269	0.018	121	-0.090	0.439
X14086	486	-0.130	0.046	46	-0.321	0.209	143	-0.181	0.298	240	-0.076	0.648	103	0.075	0.680
leucylalanine (X14189) pos. mode	510	-0.308	8.58 x10-07	47	0.036	0.879	152	-0.792	2.19 x10-05	248	-0.756	6.03 x10-06	110	-0.218	0.184
α-glutamyltyrosine (X14205)	169	-0.180	0.113	4	0.242	0.877	61	-0.498	0.379	84	-0.341	0.491	24	0.205	0.653
phenylalanylserine (X14208)	408	-0.408	9.75 x10-08	15	0.059	0.892	131	-0.697	0.014	194	-0.415	0.121	83	0.232	0.439
leucylalanine (X14304) neg. mode	488	-0.302	3.58 x10-06	48	0.094	0.628	147	-1.017	1.76 x10-07	237	-0.961	4.62 x10-08	104	-0.408	0.015

For column description see Table 1; due to the family structure linear mixed-effects models were used instead of linear regressions; data for the ratios aspartylphenylalanine/X11805 and aspartylphenylalanine/phenylalanylleucin (X14450) was not reported in TwinsUK.